StockNews.com Initiates Coverage on DBV Technologies (NASDAQ:DBVT)

StockNews.com started coverage on shares of DBV Technologies (NASDAQ:DBVT) in a research note released on Thursday. The firm issued a hold rating on the stock.

Separately, HC Wainwright reduced their price target on shares of DBV Technologies from $20.00 to $10.00 and set a buy rating on the stock in a research report on Wednesday, May 8th.

DBV Technologies Stock Performance

Shares of DBVT opened at $0.93 on Thursday. The company’s fifty day moving average is $0.94 and its 200 day moving average is $1.34. DBV Technologies has a fifty-two week low of $0.50 and a fifty-two week high of $3.70. The stock has a market capitalization of $90.01 million, a PE ratio of -1.11 and a beta of 0.69.

DBV Technologies (NASDAQ:DBVT) last announced its quarterly earnings results on Tuesday, May 7th. The company reported ($0.28) earnings per share for the quarter, topping the consensus estimate of ($0.44) by $0.16. DBV Technologies had a negative net margin of 530.89% and a negative return on equity of 56.76%. The company had revenue of $1.41 million for the quarter, compared to analysts’ expectations of $3.20 million. As a group, research analysts forecast that DBV Technologies will post -1.22 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in DBV Technologies stock. Cowen AND Company LLC bought a new stake in shares of DBV Technologies S.A. (NASDAQ:DBVT) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 50,986 shares of the company’s stock, valued at approximately $49,000. 71.74% of the stock is owned by hedge funds and other institutional investors.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.